AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
Log in

OTCMKTS:QTXBQuantrx Biomedical Stock Price, Forecast & News

$0.0046
0.00 (0.00 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.01
Volume21,000 shs
Average Volume190,154 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta0.57
QuantRx Biomedical Corporation engages in the development and commercialization patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infections, urinary incontinences, general catamenial uses, and other medical needs. It also provides InSync, a feminine hygienic interlabial padand; Unique miniform, which is available as a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad, for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. The company was incorporated in 1986 and is based in Tualatin, Oregon.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:QTXB
CUSIPN/A
CIKN/A
Phone212-980-2235

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.02) per share

Profitability

Net Income$-620,000.00

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive QTXB News and Ratings via Email

Sign-up to receive the latest news and ratings for QTXB and its competitors with MarketBeat's FREE daily newsletter.

Quantrx Biomedical (OTCMKTS:QTXB) Frequently Asked Questions

How has Quantrx Biomedical's stock been impacted by COVID-19 (Coronavirus)?

Quantrx Biomedical's stock was trading at $0.0046 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, QTXB shares have increased by 0.0% and is now trading at $0.0046. View which stocks have been most impacted by Coronavirus.

Has Quantrx Biomedical been receiving favorable news coverage?

Headlines about QTXB stock have trended negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Quantrx Biomedical earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news about Quantrx Biomedical.

Who are some of Quantrx Biomedical's key competitors?

What other stocks do shareholders of Quantrx Biomedical own?

Who are Quantrx Biomedical's key executives?

Quantrx Biomedical's management team includes the following people:
  • Dr. Shalom Z. Hirschman, Chairman, CEO & Principal Accounting Officer (Age 83)

What is Quantrx Biomedical's stock symbol?

Quantrx Biomedical trades on the OTCMKTS under the ticker symbol "QTXB."

How do I buy shares of Quantrx Biomedical?

Shares of QTXB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quantrx Biomedical's stock price today?

One share of QTXB stock can currently be purchased for approximately $0.00.

What is Quantrx Biomedical's official website?

The official website for Quantrx Biomedical is www.quantrx.com.

How can I contact Quantrx Biomedical?

Quantrx Biomedical's mailing address is 10190 SW 90TH AVENUE, TUALATIN OR, 97062. The company can be reached via phone at 212-980-2235.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.